Special Issue "Cellular Pathogenesis of Pulmonary Arterial Hypertension"
Deadline for manuscript submissions: 30 April 2021.
Interests: pulmonary arterial hypertension; chronic thromboembolic pulmonary hypertension; angiogenesis; inflammation
Pulmonary arterial hypertension is a rare and devastating condition, characterized by the remodeling and the obstruction of pulmonary microvessels and resulting in increased pulmonary vascular resistance, elevated pulmonary arterial pressures, and right ventricular failure. Despite the development of various drugs during the past 3 decades, the disease cannot be cured and the prognosis remains unacceptable, with currently available drugs displaying vasodilatory effects but failing to target the pulmonary vascular remodeling. Pulmonary arterial hypertension can be either idiopathic, heritable or associated with other conditions such as connective tissue diseases, congenital heart diseases, drug/toxin intake, portal hypertension, schistosomiasis, and human immunodeficiency virus. When PAH occurs in a hereditary context, germline mutations in various genes have been identified. The pathophysiological process of PAH is an intricate process that involves vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, and thrombosis.
This Special Issue aims to provide comprehensible knowledge regarding recently identified mechanisms of the cellular pathogenesis of pulmonary arterial hypertension, which could open future and innovative treatment options and strategies.
Consequently, we warmly invite the community to submit original articles or reviews covering the abovementioned field. Please make sure that the paper matches the scope of our journal. https://www.mdpi.com/journal/cells/about
We look forward to your contributions.
Dr. Rozenn Quarck
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pulmonary arterial hypertension
- extra cellular matrix
- vascular remodeling
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
1. Author: Dr. Sophie Nadaud;
Tentative title: Role of lung Stem/Progenitor Cells in the Pulmonary Vascular Remodeling
2. Author: Dr. Frederic Perros;
Tentative title: Iron Deficiency in Pulmonary Arterial Hypertension: a Deep Dive into the Mechanisms
3. Author: Prof. Dr. Andrea Olschewski;
Tentative title: GLP-1 Pathway in PAH